Literature DB >> 24115725

Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.

Massimiliano Tognolini1, Matteo Incerti, Daniele Pala, Simonetta Russo, Riccardo Castelli, Iftiin Hassan-Mohamed, Carmine Giorgio, Alessio Lodola.   

Abstract

Lithocholic acid (LCA), a physiological ligand for the nuclear receptor FXR and the G-protein-coupled receptor TGR5, has been recently described as an antagonist of the EphA2 receptor, a key member of the ephrin signalling system involved in tumour growth. Given the ability of LCA to recognize FXR, TGR5, and EphA2 receptors, we hypothesized that the structural requirements for a small molecule to bind each of these receptors might be similar. We therefore selected a set of commercially available FXR or TGR5 ligands and tested them for their ability to inhibit EphA2 by targeting the EphA2-ephrin-A1 interface. Among the selected compounds, the stilbene carboxylic acid GW4064 was identified as an effective antagonist of EphA2, being able to block EphA2 activation in prostate carcinoma cells, in the micromolar range. This finding proposes the "target hopping" approach as a new effective strategy to discover new protein-protein interaction inhibitors.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug design; protein-protein interactions; receptors; structure-activity relationships; virtual screening

Mesh:

Substances:

Year:  2013        PMID: 24115725     DOI: 10.1002/cmdc.201300305

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.

Authors:  I Hassan-Mohamed; C Giorgio; M Incerti; S Russo; D Pala; E B Pasquale; I Zanotti; P Vicini; E Barocelli; S Rivara; M Mor; A Lodola; M Tognolini
Journal:  Br J Pharmacol       Date:  2014-08-28       Impact factor: 8.739

2.  UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice.

Authors:  Claudio Festuccia; Giovanni Luca Gravina; Carmine Giorgio; Andrea Mancini; Cristina Pellegrini; Alessandro Colapietro; Simona Delle Monache; Maria Giovanna Maturo; Roberta Sferra; Paola Chiodelli; Marco Rusnati; Annamaria Cantoni; Riccardo Castelli; Federica Vacondio; Alessio Lodola; Massimiliano Tognolini
Journal:  Oncotarget       Date:  2018-05-11

3.  Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.

Authors:  Parima Udompholkul; Carlo Baggio; Luca Gambini; Yu Sun; Ming Zhao; Robert M Hoffman; Maurizio Pellecchia
Journal:  Molecules       Date:  2021-06-17       Impact factor: 4.411

4.  Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.

Authors:  Ahmed F Salem; Si Wang; Sandrine Billet; Jie-Fu Chen; Parima Udompholkul; Luca Gambini; Carlo Baggio; Hsian-Rong Tseng; Edwin M Posadas; Neil A Bhowmick; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2018-02-27       Impact factor: 7.446

5.  Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents.

Authors:  Ahmed F Salem; Luca Gambini; Parima Udompholkul; Carlo Baggio; Maurizio Pellecchia
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-10

Review 6.  Targeting EphA2 in cancer.

Authors:  Ta Xiao; Yuhang Xiao; Wenxiang Wang; Yan Yan Tang; Zhiqiang Xiao; Min Su
Journal:  J Hematol Oncol       Date:  2020-08-18       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.